Cell Therapy Human Raw Materials Market Research Report: Information By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, [Proteins, Growth Factors, Nucleotides, and Other Supplements], Reagents & Buffers, and Other Raw Materials), By End-User (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, and Academic & Research Institutions), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

Global Cell Therapy Human Raw Materials Market Overview

 Cell Therapy Human Raw Materials Market Size was valued at USD 2.9 Billion in 2022. The Cell Therapy Human Raw Materials market industry is projected to grow from USD 3.5 Billion in 2023 to USD 18.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.60% during the forecast period (2024 - 2032). The rising demand for cell therapies and advancements in biotechnology are the primary drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cell Therapy Human Raw Materials Market Trends

Growing advancements in manufacturing technologies are driving the market growth.

Advanced sensors, automation capabilities, and control systems in next-generation bioreactor systems provide for fine control over the environment of the cell culture, maximizing productivity and growth while lowering the danger of contamination. Single-use technologies include disposable bags, tubing assemblies, and bioreactors that eliminate the need for cleaning and sterilizing. This simplifies manufacturing processes and allows for flexible, affordable production at different quantities. In particular, for cell treatments meant for clinical use, closed system processing reduces the need for open operations, enhancing product quality and safety and lowering the danger of contamination. Automating repetitive operations, improving process consistency, and increasing throughput can include automation and robotics into cell therapy manufacturing processes to minimize human error and save labor expenses.

Cell therapy is expanding due to the growing popularity of regenerative medicine, creating a need for certain raw human resources necessary for the novel medical strategy. Regenerative medicine has attracted much interest and support because it uses cell-based therapies to treat various illnesses and harness the body's healing abilities. This renewed interest is due to the possibility of transforming treatment approaches and offering new treatments for ailments for which few effective treatments exist.

The Keck School of Medicine at USC received a USD 2 million grant from the California Institute of Regenerative Medicine (CIRM) in October 2023 to improve its newly created cGMP Laboratory. This cutting-edge laboratory is intended to promote early-stage investigations into gene and cell therapies that are therapeutically feasible. The development of cutting-edge technological capabilities, efficient operations, and strict protocols required for the successful translation of these medicines from the laboratory to clinical applications is anticipated to be supported by the money from the CIRM grant. Similarly, in August 2023, researchers at City of Hope were awarded USD 32.3 million by the California Institute for Regenerative Medicine (CIRM) to support three innovative phase 1 clinical trials. These clinical studies evaluate new cell and gene therapy treatments for individuals with severe aplastic anemia, acute myeloid leukemia, and HIV.

Furthermore, an increasing range of raw materials specifically designed for these targeted therapeutic applications is required as cell therapy shows promise in treating ailments other than cancer and conventional indications like autoimmune diseases, neurodegenerative diseases, and cardiovascular conditions. An increase in clinical trials investigating the safety and effectiveness of cell treatments for novel disease targets results from the expansion of indications. The market for raw materials is being driven by the need for large amounts of raw materials for cell culture, expansion, and characterization, which are necessary for these trials. Thus driving the Cell Therapy Human Raw Materials market revenue.

Cell Therapy Human Raw Materials Market Segment Insights

Cell Therapy Human Raw Materials Product Insights

Based on Product, the   Cell Therapy Human Raw Materials market segmentation includes cell culture media, cell culture sera, cell culture supplements, [proteins, growth factors, nucleotides, and other supplements], reagents & buffers, and other raw materials. In 2023, the cell culture supplements segment dominated the market due to the growing need for cell-based medicines that do not involve animals. With initiatives like the development of new products and company expansion, many industry players are actively investigating unexplored prospects in the market. Moreover, the market share of growth factors is the highest among supplements for cell culture. Supplements for cell culture offer a way to attain serum-free conditions without sacrificing the nutrients and growth elements required for healthy cell growth. For example, a 2020 study described the sequential delivery of growth factors and cytokines released from cryogel, which enhanced tissue regeneration and sped up wound healing.

The cell culture media category is anticipated to be the fastest growing. The specific and regulated environment that cell culture media offers, along with vital nutrients and growth agents, is crucial for the survival and growth of cells. Researchers and manufacturers can optimize parameters in this controlled environment to ensure the repeatability and scalability of cell cultures for therapeutic applications. To improve the efficacy of the cell treatment procedure, many businesses also invest a lot of money in creating cell culture media. For example, Lonza released TheraPEAK T-VIVO Cell Culture Medium in May 2023 to accelerate cell therapy's advancement.

Cell Therapy Human Raw Materials End-Use Insights

Based on End-Use, the   Cell Therapy Human Raw Materials market segmentation includes biopharmaceutical & pharmaceutical companies, CROs & CMOs, and academic & research institutions. In 2023, the biopharmaceutical & pharmaceutical companies category generated the most income. This is attributed to rising R&D expenditures, increased need for cell-based treatments, and the availability of cutting-edge medical facilities. As a result, businesses invest significantly in research and development, utilizing their biotechnology knowledge to find and create innovative cell treatments. For example, in May 2023, NewBiologix successfully obtained USD 50 million in investment to advance the development of its cutting-edge technology platform to improve the processes involved in manufacturing gene and cell therapies.

The cell therapy human raw materials CROs & CMOs category is predicted to expand quickly over the projected period. Contract Research Organizations (CROs) are a vital resource for preclinical and clinical research. Their competence in trial design, patient recruiting, and regulatory compliance helps to facilitate the development of cell treatments. Conversely, biopharmaceutical businesses lacking the necessary skills might benefit from better and more affordable manufacturing options provided by Contract Manufacturing Organizations (CMOs). Therefore, due to offering extremely specialized services, CROs and CMOs have become important figures in the end-user segment.

Figure 1:   Cell Therapy Human Raw Materials Market, by End-Use, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Cell Therapy Human Raw Materials Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Cell Therapy Human Raw Materials market will dominate, owing to the region's dominance, which can be attributed to supportive government policies, an increasing need for innovative treatments, and coordinated efforts by significant industry players to improve cell therapy products that treat a range of chronic illnesses. Furthermore, North America is home to many well-known businesses that produce and sell cell-based products, increasing demand for human raw materials for cell therapy and consequently driving market expansion.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2:   Cell Therapy Human Raw Materials Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Cell Therapy Human Raw Materials market is the second-largest market share. The European Medicines Agency (EMA) and the Committee for Advanced Therapies (CAT) are two prominent regulatory bodies in Europe with a well-established regulatory framework for cell therapy products. These organizations offer precise criteria and regulatory approval routes. The market launch of cell therapy products is made easier by this regulatory framework that promotes innovation, increasing demand for human raw materials. Further, the German Cell Therapy Human Raw Materials market held the largest market share, and the UK Cell Therapy Human Raw Materials market was the fastest-growing market in the European region.

The Asia-Pacific Cell Therapy Human Raw Materials Market is expected to grow at the fastest CAGR from 2024 to 2032. This increase is attributed to the growing demand for sophisticated cell therapies and the increased focus on biotechnology. Major industry players' installation of manufacturing facilities, strategic alliances, and heightened R&D activities drive the market's growth. Moreover, China’s Cell Therapy Human Raw Materials market held the largest market share, and the Indian Cell Therapy Human Raw Materials market was the fastest-growing market in the Asia-Pacific region.

Cell Therapy Human Raw Materials Key Market Players & Competitive Insights

Leading industry participants are making significant R&D investments to broaden their product offerings, contributing to the further expansion of the Cell Therapy Human Raw Materials market. In addition, market players are engaging in various strategic endeavors to broaden their worldwide reach. Significant developments in the market include introducing new products, agreements under contracts, mergers and acquisitions, increased investment, and cooperation with other entities. It must provide affordable products for the Cell Therapy Human Raw Materials sector to grow and thrive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers use in the worldwide Cell Therapy Human Raw Materials industry to assist customers and expand the market sector. The Cell Therapy Human Raw Materials sector has recently provided some of the biggest medical benefits. Major players in the Cell Therapy Human Raw Materials market, including Thermo Fisher Scientific, Inc, ACROBiosystems, STEMCELL Technologies, Merck KGaA, Actylis, RoosterBio, Inc., PromoCell GMBH, Grifols, S.A., Charles River Laboratories, Danaher, Akron Biotech, BioIVT, GeminiBio, AllCells, and CGT  , and others, are attempting to increase market demand by investing in research and development operations.

Science and technology are the focus of Merck KGaA (Merck), a division of E. Merck KG. In addition to developing liquid crystal mixes, organic light-emitting diode (OLED) materials, cosmetic active ingredients, coating pigments, and high-tech materials, it also finds, develops, and produces prescription medications for treating cancer, multiple sclerosis, and infertility. Additionally, Merck offers many products, including flow cytometry kits and instruments, end-to-end systems, test assays, analytical reagents, gene editing tools, cell lines, antibodies, and microbiological and biomonitoring products. The business caters to the markets for performance materials, healthcare, and life sciences. Merck KGaA invested USD 24.38 million in July 2023 to increase the manufacturing of cell culture medium in the United States. It increased the Lenexa facility's capacity to produce cell culture medium.

Serving the   biotechnology sector, GeminiBio focuses on assisting clients in expediting the development of life-improving biotherapeutics, from fundamental research to commercial production. Regardless of batch size, the company primarily focuses on developing catalog and bespoke cGMP bioprocess liquids that drastically streamline clients' manufacturing workflows. It also specializes in developing cell culture products and solutions that assist customers in streamlining their discovery, development, and production processes. GeminiBio is a California company located in West Sacramento with two manufacturing buildings totaling 57,000 square feet. The company's cell culture sera and bioprocess liquid manufacturing facilities are divided between animal component and animal origin-free cGMP manufacturing to fulfill the exacting requirements of biotechnology research and production customers. Gemini Bio announced in March 2023 that an advanced cGMP bioprocess liquid manufacturing facility would open its doors in West Sacramento, California. This improved its capacity to satisfy the expanding needs of the markets for cell and gene therapy and biotechnology.

Key Companies in the Cell Therapy Human Raw Materials market include

• Thermo Fisher Scientific, Inc


• ACROBiosystems


• STEMCELL Technologies


• Merck KGaA


• Actylis


• RoosterBio, Inc.


• PromoCell GMBH


• Grifols, S.A.


• Charles River Laboratories


• Danaher


• Akron Biotech


• BioIVT


• GeminiBio


• AllCells


• CGT

Cell Therapy Human Raw Materials Industry Developments

November 2023: Release of GMP-grade DLL4 was announced by ACROBiosystems. Among the few products on the market made under GMP guidelines is this recombinant, soluble form of Delta-like Ligand 4 (DLL4), utilized in producing stem cells.

June 2023: The U.S. cell therapy company that produces allogeneic genetically modified CAR-NK cells from umbilical cord blood has formalized a cooperative partnership with StemCyte. Under the agreement, StemCyte is committed to providing vital raw materials for advancing allogeneic cell therapy product development  ly.

Cell Therapy Human Raw Materials Market Segmentation

Cell Therapy Human Raw Materials Product Outlook

• Cell Culture Media


• Cell Culture Sera


• Cell Culture Supplements
  
  
  
  • Proteins
  
  
  • Growth Factors
  
  
  • Nucleotides
  
  
  • Other Supplements
  
  
  
  


• Reagents & Buffers


• Other Raw Materials

Cell Therapy Human Raw Materials End-Use Outlook

• Biopharmaceutical & Pharmaceutical Companies


• CROs & CMOs


• Academic & Research Institutions

Cell Therapy Human Raw Materials Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America